Method For Producing Fusion Protein Having Igg Fc Domain

Patent No. EP3363811 (titled "Method For Producing Fusion Protein Having Igg Fc Domain") was filed by Alteogen on Oct 14, 2016. The application was issued on Apr 19, 2023.

Patent Summary

This method produces aflibercept, a therapeutic fusion protein comprising a human immunoglobulin G (IgG) Fc domain and a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor (specifically immunoglobulin-like domain 2 of a first VEGF receptor and domain 3 of a second VEGF receptor). The process involves culturing cells, such as CHO-K1, at an initial temperature of 35.0°C to 38.0°C. Upon reaching a cell density of 1×10⁶ to 1×10⁸ cells/ml, the culture temperature is decreased to 30.0°C to 34.0°C. This temperature shift increases protein expression levels, enhances cell growth and viability, and inhibits the generation of fusion protein aggregates, thereby improving overall productivity and quality. The method may further include recovering the target protein from the culture broth.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3363811

ALTEOGEN
Application Number
EP16855776A
Filing Date
Oct 14, 2016
Status
Granted And Under Opposition
Mar 17, 2023
Publication Date
Apr 19, 2023